ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Phase 1 looking good for Lilly except the usual problem

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Mar 31, 2023 4:33pm

135 Views

Post# 35372769

RE:Phase 1 looking good for Lilly except the usual problem

PMN310 Key Features

Our PMN310 program is a next-generation, potential best-in-class anti-amyloid therapy in development.

Highly selective for only misfolded, toxic oligomers
- Does not bind monomer
- Does not bind plaque or vascular deposits
  - Potentially lower risk of amyloid-related imaging abnormality-edema (ARIA-E) (brain swelling) side effect
Doses may not to be limited by off-target binding or side effects
All dosed PMN310 will be focused on neutralizing toxic oligomers
- Potentially more favorable clinical efficacy profile